Abstract: The present application provides a method for genotyping M. tuberculosis, comprising obtaining amplifying and obtaining a first DNA fragment from a DNA sample by using one or more primer sets selected from the group consisting of primer sets 1 to 25 (SEQ ID Nos. 1 to 50); amplifying and obtaining a second DNA fragment from the obtained first DNA fragment by using one or more extension primers selected from the group consisting of SEQ ID Nos. 51 to 75; and detecting the second DNA fragment by using mass spectrometry, particularly by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Abstract: The present invention relates to a method and a pharmaceutical composition for treating an HCC negative for HBV/HCV, comprising administering a subject in need thereof an therapeutically effective amount of an inhibitory agent to control the genetic alteration of lipid homeostasis associated genes, including CD36 amplification and ABCG4 deletion. According to the present invention, medicines targeting the lipid metabolism pathways are developed to treat HCC patients with CD36 amplification and/or ABCG4 deletion.

Abstract: The present application provides a method for genotyping M. tuberculosis, comprising obtaining amplifying and obtaining a first DNA fragment from a DNA sample by using one or more primer sets selected from the group consisting of primer sets 1 to 25 (SEQ ID Nos. 1 to 50); amplifying and obtaining a second DNA fragment from the obtained first DNA fragment by using one or more extension primers selected from the group consisting of SEQ ID Nos. 51 to 75; and detecting the second DNA fragment by using mass spectrometry, particularly by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Abstract: The present application provides a primer set for genotyping M. tuberculosis selected from the group consisting of primer sets 1-25 (SEQ ID Nos. 1-50), and also provides an extension primer for genotyping M. tuberculosis selected from one of the group consisting of SEQ ID Nos. 51-75. The present application provides a combination of single-nucleotide polymorphism markers of M. tuberculosis. Further, the present application provides a method and a kit for genotyping M. tuberculosis.

Abstract: The present invention is related to a Cisd2 knockout mouse with phenotype comprising mitochondrial breakdown and dysfunction, wherein Cisd2 is defined as SEQ ID NO. 1. The present invention is also related to a mouse model of Wolfram Syndrome 2 (WFS2) disease consisting of a Cisd2 knockout mouse. The present invention is further related to a method for screening a candidate agent for preventing or treating WFS2 disease.

Abstract: The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90?), and heat-shock protein 90, beta isoform (hsp90?). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.

Abstract: The present invention relates to a Klebsiella pneumoniae gene-deleted mutant and its producing methods. The main objective of this invention is to construct a Klebsiella pneumoniae tonB deletion mutant used as an immunogenically effective amount of a live attenuated vaccine against the community-acquired pyogenic liver abscess, where the tonB gene was deleted. The tonB deletion mutant maintained the structure of the capsular polysaccharide on cell membrane surface, and induced no disease on the mouse after injection. In addition, the tonB deletion mutants induced the immunity against pyogenic liver abscess caused by Klebsiella pneumoniae.

Abstract: Methods, compounds, and kits for the diagnosis or screening of osteonecrosis are described, and the development of animal models for COL2A1 function in osteonecrosis is put forth. Novel mutations in the COL2A1 gene are identified that are associated with avascular necrosis of the femoral head. Methods of treatment of osteonecrosis and avascular necrosis of the femoral head, including gene therapy approaches comprising introduction of COL2A1 nucleic acid are contemplated.

Abstract: The present invention is related to a Cisd2 knockout mouse with phenotype comprising mitochondrial breakdown and dysfunction, wherein Cisd2 is defined as SEQ ID NO. 1. The present invention is also related to a mouse model of Wolfram Syndrome 2 (WFS2) disease consisting of a Cisd2 knockout mouse. The present invention is further related to a method for screening a candidate agent for preventing or treating WFS2 disease.

Abstract: Diagnosis of lung cancer based on the expression level(s) of one or more GTPase of Immunity-Associated Proteins (GIMAP) and method for identifying anti-lung cancer drug candidates based on their up-regulation of GIMAP activity.

Abstract: The present invention relates to a method of identifying a human subject having an elevated risk of gout and/or hyperuricemia by detecting the occurrence of at least one SNP associated with an elevated risk of gout in an ALPK1 gene in a biological sample from the subject, or by determining the expression level of an ALPK1 gene in a biological sample from the subject. Also disclosed is an isolated nucleic acid molecule, its complement or gene variant comprising at least one of the polymorphisms identified herein to be associated with gout and/or hyperuricemia, a kit for performing a diagnostic test to identify a human subject having an elevated risk of gout and/or hyperuricemia, and a method of selecting or identifying a compound useful for treating gout and/or hyperuricemia.

Abstract: An aging animal model and a method for screening an agent for treating or preventing aging associated phenotypes or delaying onset of aging.

Abstract: The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90?), and heat-shock protein 90, beta isoform (hsp90?). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.

Abstract: Methods, compounds, and kits for the diagnosis or screening of osteonecrosis are described, and the development of animal models for COL2A1 function in osteonecrosis is put forth. Novel mutations in the COL2A1 gene are identified that are associated with avascular necrosis of the femoral head. Methods of treatment of osteonecrosis and avascular necrosis of the femoral head, including gene therapy approaches comprising introduction of COL2A1 nucleic acid are contemplated.